Unknown

Dataset Information

0

Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells.


ABSTRACT: Anti-angiogenic therapy is an important strategy to limit growth, development and expansion of solid tumors. However, resistance to VEGF-targeting agents may develop, due to activation of alternative pro-angiogenic pathways, indicating the need of multiple target strategy. Here we obtained tumor endothelial cells (TEC) either from total renal carcinomas or from renal cancer stem cells (CSC-TEC) and we tested the effect of a CD105 targeting monoclonal antibody, TRC105, alone or in association with anti-VEGF drugs. We demonstrated that TRC105 impaired the ability of TEC and CSC-TEC to organize in tubular structures, whereas it did not limit proliferation or survival. The combination of TRC105 with different anti-angiogenic drugs showed a synergistic effect of TRC105 only in combination with the tyrosine kinase inhibitor Sunitinib. In particular, TRC105 plus Sunitinib reduced tubulogenesis, proliferation and survival of CSC-TEC and tumor-derived TEC in a similar manner. At a molecular level, we showed that the combination of TRC105 and Sunitinib induced the phosphorylation of Smad 2/3 to promote endothelial cell death. Moreover, TRC105 enhanced the inhibitory effect of Sunitinib on VEGF signaling and reduced VEGFR2-Akt-Creb activation, suggesting a molecular cooperation between the two drugs. Our results highlight that the combined inhibition of VEGF and TGF-? pathway may have a potential use in renal cell carcinoma therapy.

SUBMITTER: Brossa A 

PROVIDER: S-EPMC5978257 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells.

Brossa Alessia A   Buono Lola L   Bussolati Benedetta B  

Oncotarget 20180427 32


Anti-angiogenic therapy is an important strategy to limit growth, development and expansion of solid tumors. However, resistance to VEGF-targeting agents may develop, due to activation of alternative pro-angiogenic pathways, indicating the need of multiple target strategy. Here we obtained tumor endothelial cells (TEC) either from total renal carcinomas or from renal cancer stem cells (CSC-TEC) and we tested the effect of a CD105 targeting monoclonal antibody, TRC105, alone or in association wit  ...[more]

Similar Datasets

| S-EPMC7566100 | biostudies-literature
| S-EPMC4295225 | biostudies-literature
| S-EPMC7179003 | biostudies-literature
| S-EPMC5726867 | biostudies-literature
| S-EPMC9358462 | biostudies-literature
| 2077752 | ecrin-mdr-crc
| S-EPMC164704 | biostudies-literature
2024-10-24 | GSE152269 | GEO
2023-10-24 | PXD040902 | Pride
| S-EPMC3904600 | biostudies-literature